Growth-oriented investor and operating executive with experience sourcing and scaling technology and healthcare businesses across North America and Europe. Christopher Griffith brings expertise in corporate strategy, M&A execution and board-level governance, focusing on SaaS, fintech and healthcare services. Prior roles span investments, operating leadership and advisory work; holds a graduate business degree and is active in venture and private equity deal syndication.
Growth-oriented investor and operating executive with experience sourcing and scaling technology and healthcare businesses across North America and Europe. Christopher Griffith brings expertise in corporate strategy, M&A execution and board-level governance, focusing on SaaS, fintech and healthcare services. Prior roles span investments, operating leadership and advisory work; holds a graduate business degree and is active in venture and private equity deal syndication.
Adopts a growth-oriented, operationally grounded investment approach focused on SaaS, fintech and healthcare services across North America and Europe. Prefers founder-led companies where active board engagement, strategic M&A and scalable go-to-market execution accelerate value creation. Allocates capital to recurring-revenue models with unit-economics visibility, backing rounds that fund product-market fit and commercial scaling. Risk managed by stage diversification, deep due diligence, and hands-on operational involvement to de-risk execution over a 3–7 year horizon.
Adopts a growth-oriented, operationally grounded investment approach focused on SaaS, fintech and healthcare services across North America and Europe. Prefers founder-led companies where active board engagement, strategic M&A and scalable go-to-market execution accelerate value creation. Allocates capital to recurring-revenue models with unit-economics visibility, backing rounds that fund product-market fit and commercial scaling. Risk managed by stage diversification, deep due diligence, and hands-on operational involvement to de-risk execution over a 3–7 year horizon.
| Trades 2421 | Longs Won 1759/2421 72% | Profit Factor 9.6 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $449,184.56 |
| Average Win $137,855.22 | Best Trade (Mar 31) $9.06M | Sharpe Ratio -10.52 |
| Average Loss -$38,139.06 | Worst Trade (Aug 25) -$3.72M | Z-Score 23 (100%) |
| Commissions $0 | Avg. Trade Length 1y 4m 4w | Expectancy $89,731.21 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 19,231 | 17,308 | 15,385 | 13,462 | 11,538 | 9,615 | 7,692 | 5,769 | 3,846 | 1,923 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AAPL Apple Inc. | 72,741 | $14M | $22.47M | - | $8.47M | 60.54% | -7.354% |
ABBV AbbVie Inc. | 21,670 | $3.53M | $5.44M | - | $1.9M | 53.86% | -2.513% |
ABT Abbott Laboratories | 21,947 | $2.42M | $2.32M | - | -$103,245.51 | -4.26% | +0.085% |
ACHR Archer Aviation Inc. | 178,188 | $1.3M | $826,792.32 | - | -$477,585.86 | -36.61% | -2.11% |
ADI Analog Devices, Inc. | 2,410 | $479,121.24 | $885,458.1 | - | $406,336.86 | 84.81% | +0.202% |
AGZ iShares Agency Bond ETF | 2,456 | $269,388.82 | $266,328.64 | - | -$3,060.18 | -1.14% | -0.12% |
AIG American International Group Inc. | 22,161 | $1.58M | $1.74M | - | $164,437.03 | 10.43% | -0.393% |
AMAT Applied Materials, Inc. | 6,045 | $1M | $3.07M | - | $2.07M | 206.39% | +1.176% |
AMD Advanced Micro Devices, Inc. | 9,178 | $1.34M | $4.37M | - | $3.03M | 226.92% | -1.904% |
AMGN Amgen Inc. | 31,144 | $9.4M | $12M | - | $2.59M | 27.55% | -0.64% |
AMZN Amazon.com Inc | 43,401 | $6.96M | $11.79M | - | $4.83M | 69.4% | +15.321% |
ANET Arista Networks, Inc. | 9,582 | $1.07M | $1.73M | - | $662,076.97 | 62.11% | +5.456% |
APD Air Products and Chemicals, Inc. | 5,975 | $1.64M | $1.76M | - | $124,657.63 | 7.61% | -1.769% |
APO Apollo Global Management, Inc. | 13,024 | $1.3M | $1.64M | - | $337,527.89 | 26% | +4.441% |
ARCC Ares Capital Corporation | 11,431 | $249,721.04 | $214,445.56 | - | -$35,275.48 | -14.13% | -0.372% |
ARKK ARK Innovation ETF Fund | 6,072 | $294,528.05 | $432,569.28 | - | $138,041.23 | 46.87% | -2.277% |
ASML ASML Holding N.V. New York Registry Shares | 178 | $120,228.24 | $289,962 | - | $169,733.76 | 141.18% | -1.359% |
AVGO Broadcom Inc. | 35,058 | $5.86M | $13.65M | - | $7.78M | 132.7% | +0.371% |
AXP American Express Company | 6,235 | $1.24M | $2.1M | - | $860,249.29 | 69.58% | -0.376% |
AZN AstraZeneca PLC American Depositary Shares | 11,000 | $2.17M | $1.87M | - | -$301,446.57 | -13.91% | -0.992% |